Business Services News

Business Services News

Breaking News on Business Services

Home > Business Services Search Engine                                 

Business Services News -- Video Feeds
  • Advertising
  • Careers
  • Corporate news
  • Economy
  • Markets
  • Small Business
  • Personal Finance
  • Regulatory and Compliance
  • Business News

    Leukemia Therapeutics Market Top Players and Business Intelligence
    (I-BusinessNews.Com, August 19, 2021 ) According to the new market research report the leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period.

    Download PDF Brochure:

    Leukemia is a type of cancer originating from white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. It is identified by the spread of the disease (either acute or chronic), and by the type of the blood cell that is affected (lymphocytic or myeloid). The treatment options depend on several factors, including the phase of the disease, possible side effects, and the patient’s overall health. Leukemia therapeutic drugs are used to destroy cancer cells. This type of medication is given through the bloodstream to reach cancer cells throughout the body.

    The leukemia therapeutics market is dominated by various players offering leukemia chemotherapies, targeted drugs, and immunotherapies. The major players in this market are Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), Celgene (US). Product launches and acquisition are the key growth strategies followed by most players in this market.

    Novartis (Switzerland) is the leading company in the global leukemia therapeutics market, owing to its strong sales channel and innovative therapies. The company invested approximately 17.5% of its revenue in research and development activities. In August 2017, Novartis received the FDA approval for its CAR-T cell therapy, Kymriah (CTL019), which is used for the treatment of cancer. With this launch, Novartis became the pioneer of leukemia immunotherapies, thus maintaining its dominant position in the market. In August 2018, Novartis received the EU approval for its CAR-T cell therapy, Kymriah.

    Roche (Switzerland) holds the second position in the leukemia therapeutics market, and its leading position can be attributed to its strong product portfolio and wide geographical reach. In order to further strengthen its market position and hold a competitive edge over other players, the company adopts inorganic growth strategies such as acquisitions. The company also focuses on maintaining and enhancing its production capabilities. For example, in November 2015, Roche invested USD 295.81 million (CHF 300 million) for restructuring its manufacturing network for small molecules, which are used in the development of leukemia drugs. In November 2016, Roche launched the Centers of Research Excellence (imCORE), a network of 21 academic centers around the world to access and share technology, data, and expertise to advance the science of cancer immunotherapy. Such initiatives have helped the company maintain its market share and remain competitive in the leukemia therapeutics market.

    Based on the type of leukemia, the leukemia therapeutics market is segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Of these, the chronic myeloid leukemia segment accounted for the largest market share in 2018.

    Based on treatment type, the leukemia therapeutics market is bifurcated into chemotherapy and targeted drugs & immunotherapy. Of these, the targeted drugs & immunotherapy segment accounted for the largest market share in 2018.

    Request For Sample Pages:

    The North American market is expected to account for the largest share, globally. The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market. In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US. According to the Canadian Cancer Society, nearly 138,100 people in Canada are living with or are in remission from blood cancer (data as of 2016). In addition, nearly 22,340 Canadians of all ages were diagnosed with a form of blood cancer, including 5,900 cases of leukemia.

    Mr. Aashish Mehra
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA: +1-888-600-6441


    Mr. Aashish Mehra


    Source: EmailWire.Com


    Business News Feeds
  • Business News - Top Stories
  • Company Earnings
  • Economy
  • Personal Finance
  • Real Estate
  • Stock Markets
  • Business Services Sponsors

    Business Services Ads

    Business Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    CIO Insight
    Managed Healthcare Executive
    Mortgage Technology

    No credit cards, coupons, or promo codes required. Try it today!

    Press release service

    :: Home: :: Submit Press Release :: Subscribe to News :: Contact Us :: Help

    For unlimited press release distribution for $59 per month, call (281) 645-4086 or start posting your press releases online at

    Copyright 2008 GroupWeb Media LLC
    GroupWeb Media Network

    Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | | iT-NewsWire.Com
    | i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
    I-BusinessNews.Com is a business news service of GroupWeb Media LLC